These Small Cap Stocks Are Getting Major Attention Today

NEW YORK, NY / ACCESSWIRE / April 11, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. MNKD, OMEX, CANF and SGYP are on high volume alert. Continue reading to find out why these stocks are getting so much interest today. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.

MannKind Corp. (NASDAQ: MNKD) Is a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes patients in the United States.

Shares of MNKD are up 20% early this morning after announcing that they will host an analyst call for the investment community to learn about the company's general commercialization strategy in the US for Afrezza® (insulin human) Inhalation Powder.

After 3 down days, today is looking promising for a quick turnaround for MNKD.

Subscribe Free To Receive Alerts Like These Sent To Your Inbox Get Your Free Membership Now.

Odyssey Marine Exploration Inc. (NASDAQ: OMEX) Together with its subsidiaries, engages in deep-ocean exploration activities worldwide. The company provides exploration services, including geophysical and geotechnical assessments of seabed mineral deposits to companies.

OMEX is currently trading lower by over 50% this morning and it's not looking like it's going to get any better for the company after reporting earnings for Q4, 2015.

You don't have to be an earnings analysts to know that the report wasn't good and with their "Don Diego" dredging and phosphate sands extraction project resulting in the denial for an environmental license, the company is digging even deeper to find positive news for the near future.

Like What You See? Get These Alerts and Many More on NASDAQ Companies before They Rally, Find Out More Here.

Can-Fite BioPharma Ltd. (NYSE: CANF) Is a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and ophthalmic diseases.

Shares of CANF are trading higher today by 8% off massive volume after reporting new findings for its drug candidate, CF602, showing statistically significant full recovery from erectile dysfunction after one single dose treatment in a pre-clinical diabetic model.

This is great news for the stock that has been surging as of late. The company is finally showing signs of getting the recognition that it appears to deserve.

Get the Information You Need To Stay Informed and Up To Date On The Hottest NASDAQ Plays Get Them Here.

Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) Is a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders.

Shares of SGYP are getting slightly higher attention than usual after The Motley Fool sent out a report on the company and its progression of their constipation drug, Plecanatide.

The drug is showing good signs of relieving constipation in studies, however the report was less than warm, suggesting that SGYP still has a long road to travel before FDA approval (or FDA disapproval).

NASDAQ Stock Alerts: Check Them Out Here To Receive Our Winning NASDAQ & NYSE Stock Alerts For Free.

About TheStockExpert.com

The Stock Expert is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big news on high volume days. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments.

To receive free text message alerts on your phone, compose a new text message to the number 95577 with the word "STOCKEXPERT".

Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor's or other person's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. The Stock Expert has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding the companies reported in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words "anticipate," "intend," "estimate," "believe," "expect," "plans," "should," "potential," "forecast," and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company's actual results could differ materially from those described in any forward-looking statements contained herein. The Stock Expert is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit TheStockExpert.com/disclaimer website for a more detailed discussion of risks and disclosures.

Contact:

Justin Skibinski
The Stock Expert
info@thestockexpert.com

SOURCE: The Stock Expert